China3D printingNet, April 3, Aprecia Pharmaceuticals is the first to obtain FDA approval3D printingDrug Spritam’s company, the company has announced a collaboration with Purdue University School of Pharmacy to promote the technological and scientific development of 3D drug printing.Their cooperation will focus on developing future3D printingPharmaceutical equipment and drugs.
“Aprecia’s mission is to maximize and expand its 3DP technology platform through global partnerships, which will provide pharmaceutical solutions for unmet patient needs.” Aprecia CEO Chris Gilmore commented.Purdue University is a well-known institution, and we firmly believe that this partnership will advance our future in 3DP drug development. “
Spretam is the world’s first FDA approved3D printingThe drug, sold by Aprecia Pharmaceuticals. 3D printingPills are used to treat seizures and their porosity is higher than traditional pills, which means they dissolve and act faster in the body.
3D printingDrug “alt=”Spritam, the world’s first FDA approved3D printingDrugs” width=”620″ height=”395″ />
Spritam, the world’s first FDA approved3D printingdrug. Picture from Aprecia
ZipDose 3D printingTechnology
Aprecia Pharmaceuticals was founded in 2003, its goal is to achieve3D printingCommercial production of drugs.It plans to use powdered liquid3D printingThe technology for this operation, which was originally developed by the Massachusetts Institute of Technology (MIT) in the late 1980s, is a rapid prototyping technology.Then, Aprecia adopted powder liquid in 20073D printingTechnology to develop its own ZipDose process, which involves the use of printing fluids to bond API-containing powder layers together to form porous structures or tablets, and transform them into a conveyor belt-like system.
The porosity of the tablet is Aprecia’s ZipDose 3D printingThe main advantage of pill technology is that they have more holes than tablets made using traditional methods. Then, this means that they dissolve and act faster when drinking water. Aprecia was first approved by the FDA in 20153D printingPills, the Spritam product of this medicine is used to treat seizures in patients with epilepsy. Subsequently, the company launched the commercial production operation of the drug in the same year.
In 2017, Aprecia also announced that it had established a partnership with Cycle Pharmaceuticals Ltd. of Cambridge, UK.The two companies worked together and agreed to use Aprecia’s adhesive jet3D printingTechnology produces orphan drugs for the treatment of rare diseases.
In the new cooperation with Purdue University, the agreement will bring together faculty, research scholars and students to participate in3D printingThe joint collaboration of drug research and discovery. Eric Barker, Dean of Purdue University School of Pharmacy, explained: “As a university, our mission is to prepare the next generation of pharmaceutical leaders. The cooperation with Aprecia is fully in line with that mission. We are very much I am happy to combine our talented teachers and students with Aprecia’s successful researchers and work together to accelerate discovery in this emerging field.”
3D printing
The pill” alt=”Aprecia
3D printing
Of pills” width=”620″ height=”349″ />
Aprecia 3D printingOf pills. Picture from Aprecia Pharmaceuticals
3D printingThe state of the pill
3D printingDrugs are a rapidly developing field. Since Aprecia’s first FDA-approved pill was launched in the United States in 2016, there have been many developments. September 2019, UK3D printingThe pharmaceutical company FabRx revealed that it has developed a personalized medicine for children with a rare metabolic disorder, Maple Syrup Urine Disease (MSUD). FabRx3D printingChewable tablets are called Printlets and provide a quick, automated alternative to custom tailored therapeutic doses.
In addition, at the beginning of 2019, the UK Government’s Technology Strategy Committee Innovation UK has sought to produce3D printingThe drug project provided a grant of 650,000 pounds. The beneficiaries of the grant include FabRx and Katjes Fassin UK Ltd., a regional branch of the German confectionery company Katjes Fassin GmbH + Co. KG.The two companies focus on3D printingThe commercialization of technology, which can produce personalized medicines for human consumption.
Last month, the global pharmaceutical company Merck (Merck) revealed the development and production3D printingThe plan for the tablet computer is first for clinical trials, and then for commercial production in cooperation with AMCM, a customized additive manufacturing machine under the EOS Group.
China3D printingNet original article!
(Editor in charge: admin)
0 Comments for “APRECIA and PUDERUE University collaborate on the research and development of 3D printed medicines”